Roche Holding AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public

Established: 1896-01-15

Employees: 103.6K

Market Cap: $270.5B

Website: http://www.roche.com

Clinical Trials

A Retrospective Study to Assess the Impact of the Use of Interferon in Patients With Chronic Hepatitis C (DECISION)

Completed

Conditions: Hepatitis C, Chronic

Interventions: Drug: Conventional Interferon
Drug: Peginterferon Alfa-2a
Drug: Peginterferon Alfa-2b
Drug: Ribavirin

First Posted Date: 2011-01-21

Last Posted Date: 2016-11-29

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 660

Registration Number: NCT01280656

A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir With or Without Copegus (Ribavirin) in Interferon-Naïve Patients With Chronic Hepatitis C Genotype 1 (INFORM-SVR)

Phase 2

Completed

Conditions: Hepatitis C, Chronic

Interventions: Drug: peginterferon alfa-2a [Pegasys]
Drug: Copegus placebo
Drug: ribavirin [Copegus]
Drug: RO5024048
Drug: danoprevir
Drug: ritonavir

First Posted Date: 2011-01-17

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 170

Registration Number: NCT01278134

An Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis

Terminated

Conditions: Rheumatoid Arthritis

First Posted Date: 2011-01-14

Last Posted Date: 2016-09-15

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 95

Registration Number: NCT01277328

A Study of RO5093151 in Patients With Non-Alcoholic Fatty Liver Disease

Phase 1

Completed

Conditions: Fatty Liver, Non-alcoholic Fatty Liver Disease, NAFLD

Interventions: Drug: RO5093151
Drug: Placebo

First Posted Date: 2011-01-14

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 82

Registration Number: NCT01277094

An Observational Study on The Correlation Between Time of Initiation of Avastin (Bevacizumab) Treatment And Progression-Free Survival in Patients With Metastatic Breast Cancer (CRONOS 2)

Terminated

Conditions: Breast Cancer

First Posted Date: 2011-01-14

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 83

Registration Number: NCT01277133

An Observational Study on The Correlation Between Time of Initiation of Avastin (Bevacizumab) Treatment And Progression-Free Survival in Patients With Colorectal Cancer (CRONOS 1)

Terminated

Conditions: Colorectal Cancer

First Posted Date: 2011-01-14

Last Posted Date: 2016-09-15

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 174

Registration Number: NCT01277120

An Observational Study of Xeloda (Capecitabine) Monotherapy in Patients With Colorectal Cancer (AXEL)

Terminated

Conditions: Colorectal Cancer

First Posted Date: 2011-01-13

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 123

Registration Number: NCT01276405

A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Failed on One Prior Anti-TNF Therapy (RESET)

Phase 3

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: rituximab

First Posted Date: 2011-01-10

Last Posted Date: 2017-08-15

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 120

Registration Number: NCT01272908

A Study of Vemurafenib and GDC-0973 (Cobimetinib) in Participants With BRAFV600E Mutation-Positive Metastatic Melanoma

Phase 1

Completed

Conditions: Malignant Melanoma

Interventions: Drug: Cobimetinib
Drug: vemurafenib

First Posted Date: 2011-01-07

Last Posted Date: 2019-07-29

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 131

Registration Number: NCT01271803

Locations: 🇺🇸
The Angeles Clinic and Research Institute, Santa Monica Office, Santa Monica, California, United States
🇺🇸
UCLA Department of Medicine, Los Angeles, California, United States
🇺🇸
University of California at San Francisco, San Francisco, California, United States

and more 7 locations

A Study of Rituximab in Combination With Fludarabine and Cyclophosphamide in Participants With Chronic Lymphocytic Leukemia and Favorable Somatic Status

Phase 4

Terminated

Conditions: Lymphocytic Leukemia, Chronic

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Rituximab

First Posted Date: 2011-01-06

Last Posted Date: 2018-03-20

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 89

Registration Number: NCT01271010

Locations: 🇷🇺
Regional Clinical Oncology Despensary #1; Hematology Department, Krasnodar, Russian Federation
🇷🇺
The order of Honour pin Irkutsk regional clinical hospital; Hematology Department, Irkutsk, Russian Federation
🇷🇺
Kemerovo Regional Clinical Hospital, Kemerovo, Russian Federation

and more 7 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy